<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02166112</url>
  </required_header>
  <id_info>
    <org_study_id>Permacol Dutch Cohort Study</org_study_id>
    <nct_id>NCT02166112</nct_id>
  </id_info>
  <brief_title>The Permacol Dutch Cohort Study</brief_title>
  <official_title>The Permacol Dutch Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amphia, Breda, the Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catharina Ziekenhuis Eindhoven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Franciscus, Roosendaal, the Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Groene Hart, Gouda, the Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Havenziekenhuis, Rotterdam, the Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lievensberg, Bergen op Zoom, the Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Center Haaglanden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MC Leeuwarden, Leeuwarden, the Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Meander MC, Amersfoort, the Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MUMC+, Maastricht, the Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nij Smellinghe, Drachten, the Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>OLVG, Amsterdam, the Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Orbis MC, Sittard, the Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Reinier de Graaf gasthuis, Delft, the Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rijnstate, Arnhem, the Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spaarne ziekenhuis, Hoofddorp, the Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tergooi ziekenhuizen, Hilversum, the Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Elisabeth-TweeSteden Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Groningen, Groningen, the Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Utrecht, Utrecht, the Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VieCuri, Venlo, the Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Waterland, Purmerend, the Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zuyderland Medisch Centrum, Sittard-Geleen, the Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Incisional hernia is the most frequently seen long term complication in surgery causing much
      morbidity and even mortality in patients. Despite studies on the optimal closing technique
      for laparotomies, the risk for incisional hernia after midline incision remains about 5-20 %.
      It has been established that implementing a mesh reduces recurrence of the incisional hernia
      but still the results of repair are often disappointing. Incisional hernias can become
      increasingly complex due to complicated abdominal wall defects caused by a disturbed anatomy,
      fistulas, burst abdomen, wound and mesh infections. In these cases it is not save to repair
      the incisional hernia by means of a synthetic mesh and other augmentation tools need to be
      implemented.

      In the recent years the use of biological meshes has been gaining popularity. Recent reports
      of the use of collagen-based prosthesis have suggested that they support new vessel growth,
      do not excite a significant foreign body reaction, form fewer adhesions, are well
      incorporated into host tissues with minimal wound contraction, and can be used in grossly
      contaminated wounds with fewer infective complications. Biologic meshes are harvested from a
      source tissue and processed for medical use but they vary widely in their processing methods.
      They include tissues of human or animal origins, both chemically cross-linked and non
      cross-linked processes, and submucosal, pericardial, or dermal tissue sources. Current
      studies investigating the effectiveness of these meshes are small and have short periods of
      follow-up. These shortcomings can be explained to high cost of the meshes and unclear
      indication when to use a biological mesh.

      The aim of this study is investigate the short and long term effects of the Permacol©
      biological mesh. Also the investigators will be inquiring why a biologic mesh was used, what
      is the true indication to use a biological mesh.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incisional Hernia recurrence</measure>
    <time_frame>One and two year after initial operation</time_frame>
    <description>This parameter will be assessed by taking a history of the patient and assessing operation room reports.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mesh explantations</measure>
    <time_frame>Anytime after abdominal wall reconstruction with Permacol until two years after operation</time_frame>
    <description>This parameter will be assessed by taking a history of the patient and assessing operation room reports.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>All postoperative complications are assessed until two years after initial operation</time_frame>
    <description>This parameter will be assessed by taking a history of the patient and assessing patient reports and operation room reports.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional &quot;abdominal wall repair&quot; operations</measure>
    <time_frame>After initial abdominal wall reconstruction with Permacol until two years after initial operation</time_frame>
    <description>This parameter will be assessed by taking a history of the patient and assessing patient reports and operation room reports.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indication of Permacol usage</measure>
    <time_frame>Perioperatively</time_frame>
    <description>The indication for usage of Permacol was noted just before or just after operation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>A year or longer after initial abdominal wall reconstruction until two years after initial operation</time_frame>
    <description>This parameter will be assessed various questionnaires (ShortForm-36, EuroQOL (EQ-5D-5L), and Body Image Questionnaire).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">77</enrollment>
  <condition>Hernia of Abdominal Wall</condition>
  <condition>Biologic Implant</condition>
  <condition>Infected Hernioplasty Mesh</condition>
  <arm_group>
    <arm_group_label>Permacol mesh placement</arm_group_label>
    <description>No intervention performed</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Permacol mesh placement</intervention_name>
    <description>All patients were treated for a complex abdominal wall hernia by implantation of Permacol mesh. This intervention took place before patients were included in the cohort.</description>
    <arm_group_label>Permacol mesh placement</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The design of the trial will be a cross sectional cohort study. We will be gathering
        information from all the centers in the Netherlands who have used the Permacol© mesh in the
        past to treat complicated abdominal wall defects. Patients will be asked to return to the
        hospitals outpatient clinic. A total of around 70 patients will be included into the study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Complicated abdominal wall hernia repair

          -  Permacol© mesh implantation

        Exclusion Criteria:

          -  No signed informed consent

          -  Operation other than Complicated abdominal wall hernia repair

          -  Implant other than Permacol© mesh implantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruth Kaufmann, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Meander MC</name>
      <address>
        <city>Amersfoort</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rijnstate</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lievensberg</name>
      <address>
        <city>Bergen op Zoom</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf Gasthuis</name>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MC Haaglanden</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nij Smellinghe</name>
      <address>
        <city>Drachten</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groene Hart</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atrium MC</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tergooi ziekenhuizen</name>
      <address>
        <city>Hilversum</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spaarne ziekenhuis</name>
      <address>
        <city>Hoofddorp</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MC Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUMC+</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waterland</name>
      <address>
        <city>Purmerend</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franciscus</name>
      <address>
        <city>Roosendaal</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Havenziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orbis MC</name>
      <address>
        <city>Sittard</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TweeSteden</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VieCuri</name>
      <address>
        <city>Venlo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2014</study_first_submitted>
  <study_first_submitted_qc>June 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2014</study_first_posted>
  <last_update_submitted>April 5, 2017</last_update_submitted>
  <last_update_submitted_qc>April 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Ruth Kaufmann, MD</investigator_full_name>
    <investigator_title>PhD fellow</investigator_title>
  </responsible_party>
  <keyword>Hernia of Abdominal Wall</keyword>
  <keyword>Biologic implant</keyword>
  <keyword>Infected Hernioplasty Mesh</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hernia</mesh_term>
    <mesh_term>Hernia, Abdominal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

